NCT03009487 - A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia | Biotech Hunter

Enrollment

265

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions

HypertensionHyperlipidemias

Interventions

DRUG

Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg

co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg

DRUG

Olmesartan 40 mg, Rosuvastatin 20mg

co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).

DRUG

Amlodipine/Olmesartan 10/40mg (Combination drug)

co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg

Trial Locations (1)

Unknown

Seoul national university bundang hospital, Seoul